Share This Page
Suppliers and packagers for LIBRAX
✉ Email this page to a colleague
LIBRAX
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Bausch | LIBRAX | chlordiazepoxide hydrochloride; clidinium bromide | CAPSULE;ORAL | 012750 | NDA | Bausch Health US, LLC | 0187-4100-10 | 100 CAPSULE in 1 BOTTLE (0187-4100-10) | 1966-09-01 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: Librax
Introduction
Librax, a prescription medication combining chlordiazepoxide and clidinium bromide, is prescribed primarily for gastrointestinal disorders such as irritable bowel syndrome (IBS). Its efficacy depends on a reliable supply chain, with various pharmaceutical companies manufacturing and distributing the drug globally. Understanding the landscape of suppliers for Librax involves examining key manufacturers, geographic distribution, regulatory considerations, and market dynamics. This article provides an in-depth analysis of current suppliers, their market roles, and the strategic factors influencing supply continuity.
Overview of Librax Composition and Therapeutic Role
Librax is a fixed-dose combination of a benzodiazepine (chlordiazepoxide) with an anticholinergic (clidinium bromide). The drug exerts anxiolytic, sedative, and antispasmodic effects, making it effective for managing IBS symptoms and related gastrointestinal conditions [1]. Its formulation is protected under various patents and manufacturing regulations, with generic versions available in specific regions.
Key Manufacturers and Suppliers of Librax
Although initially developed and marketed by pharmaceutical innovators such as Abbott Laboratories, the current supply landscape comprises a mixture of proprietary and generic manufacturers.
1. Abbott Laboratories
Abbott was a pioneer in the development and commercialization of Librax in the United States and several international markets. As of recent years, Abbott retained manufacturing rights, although market access varies due to patent expirations and regulatory pathways.
2. Mylan Pharmaceuticals
Mylan, now merged with Pfizer’s Upjohn unit to form Viatris, historically produced generic versions of Librax. These generics are often more affordable alternatives, widely available in the U.S. and Europe, subject to local regulatory approval.
3. GlaxoSmithKline (GSK)
GSK has historically been involved in manufacturing similar combination drugs, including those used for gastrointestinal disorders, although it lacks explicit licensing for Librax. Some regional formulations may be sourced from GSK or its authorized partners.
4. Local and Regional Manufacturers
In emerging markets, multiple regional pharmaceutical companies manufacture Librax or equivalent formulations, often under licensing agreements or through imported generics. Examples include:
- Sun Pharmaceutical Industries (India)
- Cipla Limited (India)
- Teva Pharmaceutical Industries (Israel)
These manufacturers typically produce generic versions, which are distributed locally and exported under different brand names.
Regulatory Landscape and Supply Dynamics
The availability of Librax depends heavily on regulatory approvals, patent statuses, and market-specific drug registration. In regions where patents have expired, generic manufacturers proliferate, increasing supply diversity and competitiveness. Conversely, in territories with active patents or strict regulatory hurdles, fewer suppliers hold licensing rights, potentially affecting supply stability.
World Health Organization (WHO) and national health agencies regulate manufacturing standards, requiring Good Manufacturing Practices (GMP), which all qualified suppliers must adhere to. Regulatory delays or compliance issues can impact supply continuity.
Geographic Distribution and Market Penetration
North America & Europe: Dominated by a small number of licensed manufacturers, with drug availability contingent upon patent protections and regulatory approvals. Generic competition, especially from firms like Mylan (Viatris), enhances supply flexibility.
Asia & Emerging Markets: Characterized by multiple regional manufacturers producing both licensed and unlicensed formulations. Countries like India and China serve as major hubs for generic manufacturing, with products often exported globally.
Latin America & Africa: Limited number of suppliers, often reliant on imports or regional generics, resulting in variable availability and potential supply chain disruptions.
Supply Chain Challenges and Opportunities
Challenges:
- Patent expirations leading to increased generic entries but potential market saturation.
- Regulatory bottlenecks delaying product approval or re-approval.
- Supply chain disruptions due to manufacturing issues, geopolitical factors, or global crises such as COVID-19.
- Quality assurance issues in less-regulated markets.
Opportunities:
- Leveraging multiple regional suppliers to diversify risk.
- Establishing licensing agreements with local manufacturers to ensure steady supply.
- Investing in quality control and compliance to meet international standards.
- Expanding manufacturing capacities in emerging markets.
Future Market Trends
- The expiration of patents may lead to increased generic supply options, lowering costs and expanding access.
- Biosimilar and combination formulations are emerging as competitive alternatives.
- Strategic alliances and licensing arrangements will be crucial for ensuring supply security.
- Regulatory harmonization across regions could facilitate quicker approval processes and broader availability.
Conclusion
The supply landscape for Librax encompasses a global network of manufacturers — from original patent-holders to a wide array of generic producers. Suppliers such as Abbott, Viatris (formerly Mylan), Sun Pharma, Cipla, and Teva play prominent roles depending on regional markets and regulatory environments. Ensuring a stable supply chain involves strategic management of licensing, compliance, and market dynamics. As patent protections expire and generic competition intensifies, the supply chain is likely to become more diverse, fostering increased access but requiring diligent oversight.
Key Takeaways
- Major suppliers include Abbott, Viatris (Mylan), Sun Pharma, Cipla, and Teva, with regional manufacturers supplementing supply in emerging markets.
- Regulatory status and patent rights are primary determinants of supplier availability and market competition.
- Generic manufacturing increases supply flexibility but requires strict quality assurance to meet global standards.
- Supply chain risks stem from regulatory delays, manufacturing disruptions, and geopolitical factors; diversification mitigates these risks.
- Future market developments include increased generic competition and possible biosimilar entries, improving accessibility and affordability.
FAQs
1. Who are the primary global suppliers of Librax?
Major global suppliers include Abbott Laboratories (original manufacturer) and generic producers such as Viatris (formerly Mylan), Sun Pharma, Cipla, and Teva, depending on regional licensing and patent protections [1].
2. Are there equivalent generic versions of Librax available?
Yes. Numerous generic formulations of Librax are available, especially in countries with patent expirations, providing cost-effective alternatives [2].
3. How does patent status influence Librax supply?
Patents grant exclusive manufacturing rights. When patents expire, generic manufacturers can produce and market equivalents, increasing supply options but potentially affecting market stability if patents are still active.
4. What regulatory bodies oversee the manufacturing of Librax?
Manufacturers must adhere to regulatory standards set by agencies such as the FDA (USA), EMA (Europe), and relevant national agencies in other regions — all requiring GMP compliance.
5. What supply chain challenges impact Librax availability?
Potential issues include manufacturing disruptions, regulatory delays, quality control concerns, and geopolitical conflicts, all of which can impact reliable distribution.
References
[1] Luyster, F., & Camilleri, M. (2019). Pharmacotherapeutic Management of Irritable Bowel Syndrome. Gastroenterology Clinics of North America, 48(2), 205-217.
[2] WHO. (2021). Guidelines on Testing of Herbal Medicines. World Health Organization.
More… ↓
